

**Testing Communications on Medical Devices and Radiation-Emitting Products—(OMB Control Number 0910–New)**

FDA is authorized by section 1003(d)(2)(D) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 393(d)(2)(D)) to conduct educational and public information programs relating to the safety of regulated medical devices and radiation-emitting products. FDA must conduct needed research to ensure that such programs have the highest likelihood of being effective. Improving communications about medical devices and radiation-emitting products will involve many research methods, including individual indepth interviews, mall-intercept interviews, focus groups, self-administered surveys, gatekeeper

reviews, and omnibus telephone surveys.

The information collected will serve three major purposes. First, as formative research it will provide critical knowledge needed about target audiences to develop messages and campaigns about medical device and radiation-emitting product use. Knowledge of consumer and health care professional decisionmaking processes will provide the better understanding of target audiences that FDA needs to design effective communication strategies, messages, and labels. These communications will aim to improve public understanding of the risks and benefits of using medical devices and radiation-emitting products by providing users with a better context in which to place risk information more completely.

Second, as initial testing, it will allow FDA to assess the potential effectiveness of messages and materials in reaching and successfully communicating with their intended audiences. Testing messages with a sample of the target audience will allow FDA to refine messages while still in the developmental stage. Respondents will be asked to give their reaction to the messages in either individual or group settings.

Third, as evaluative research, it will allow FDA to ascertain the effectiveness of the messages and the distribution method of these messages in achieving the objectives of the message campaign. Evaluation of campaigns is a vital link in continuous improvement of communications at FDA.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN

Section of the act	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours	Total Operating & Maintenance Costs <sup>1</sup>
1003(d)(2)(D)	16,448	1	16,448	0.1739	2,860	\$25,239
Total	16,448	1	16,448	0.1739	2,860	\$25,239

<sup>1</sup> There are no capital costs associated with this collection of information.

Annually, FDA projects about 30 studies using a variety of research methods, and lasting an average of 0.17 hours each (varying from 0.08–1.5 hours). The operating and maintenance costs include contractor expenses for designing and conducting information collection activities, specifically, drawing samples, training interviewers, collecting and analyzing information, and reporting and disseminating findings. FDA estimates the burden of this collection of information based on prior recent experience with the various types of data collection methods described earlier. FDA is requesting this burden so as not to restrict the agency's ability to gather information on public sentiment for its proposals in its regulatory and communications programs.

Dated: July 7, 2010.

**Leslie Kux,**

*Acting Assistant Commissioner for Policy.*

[FR Doc. 2010–16973 Filed 7–12–10; 8:45 am]

**BILLING CODE 4160–01–S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Modification to the Basic Center Program Funding Opportunity Announcement**

*Program Office:* Administration on Children, Youth, & Families—Family & Youth Services Bureau.

*Funding Opportunity Title:* Basic Center Program.

*Announcement Type:* Modification.

*Funding Opportunity Number:* HHS–2010–ACF–ACYF–CY–0002.

*CFDA Number:* 93.623.

*Due Date for Applications:* 07/19/2010.

This is a Modification to the Basic Center Program Funding Opportunity Announcement (FOA), HHS–2010–ACF–ACYF–CY–0002, published to the ACF Grant Opportunities webpage on June 2, 2010, <http://www.acf.hhs.gov/grants/open/foa/view/HHS-2010-ACF-ACYF-CY-0002>. A modified FOA that incorporates the following changes was published to the ACF Grant Opportunities webpage on June 25, 2010. The application procedures are hereby modified.

**SUMMARY:** The Family and Youth Services Bureau (FYSB) is accepting applications for the Basic Center Program (BCP), which is authorized by the Runaway and Homeless Youth Act to address Runaway and Homeless Youth (RHY) problems. BCPs provide an alternative for runaway and homeless youth who might otherwise end up with law enforcement or in the child welfare, mental health, or juvenile justice systems. Each BCP must provide runaway and homeless youth with a safe and appropriate shelter; individual, family, and group counseling, as appropriate; and aftercare.

The purpose of the modification is to correct information appearing in *Section IV.2 Content and Form of Application Submission* regarding application formatting and point deduction for noncompliance with FOA instructions.

**Modification to the Published Announcement**

Please delete the following under *Section IV.2. Content and Form of Application Submission*:

“Applicants that do not adhere to the prescribed format will have points deducted from the overall total after the grant review:

Program narrative (which includes Objective and Need for Assistance, Results and Benefits, Approach, Organizational Profile, Staff and Position Data, and Budget

Justification) is not double spaced: Deduction of 5 points.

Margins less than ½ inch: Deduction of 3 points.

Font is not at least 12-point size or Times New Roman: Deduction of 2 points.”

Please replace the deleted language under *Section IV.2. Content and Form of Application Submission* with the following:

“Applications that do not adhere to the prescribed format will be converted to conform with the prescribed format. Should the conversion result in a document which exceeds 90 pages, all pages exceeding the 90-page limit will be removed and will not be considered in the reviewing process.”

All information in this modification is accurate and replaces information specified in the June 2, 2010 Funding Opportunity Announcement.

**Announcement Availability:** To access this Program Announcement please go to the ACF Grant Opportunities webpage at <http://www.acf.hhs.gov/grants/index.html> or to <http://www.Grants.gov>.

**FOR FURTHER INFORMATION CONTACT:** Victoria Marquez at 202–205–4866 and [Victoria.Marquez@acf.hhs.gov](mailto:Victoria.Marquez@acf.hhs.gov).

Dated: July 1, 2010.

**Bryan Samuels,**

*Commissioner, Administration on Children, Youth and Families.*

[FR Doc. 2010–17069 Filed 7–12–10; 8:45 am]

**BILLING CODE 4182–04–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2010–N–0274]

#### Oversight of Laboratory Developed Tests; Public Meeting; Change of Meeting Location

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing a change in location for the upcoming public meeting entitled “Oversight of Laboratory Developed Tests.” A new address is given for those attending the public meeting.

**DATES:** The public meeting will be held on July 19 and 20, 2010, from 8 a.m. to 5 p.m. each day.

**ADDRESSES:** The public meeting will be held at The Marriott Inn & Conference Center, University of Maryland University College, 3501 University Blvd. E, Hyattsville, MD 20783.

#### FOR FURTHER INFORMATION CONTACT:

Katherine Serrano, Center for Devices and Radiological Health, Food and Drug Administration 10903 New Hampshire Ave., Bldg. 66., rm 5613, Silver Spring, MD 20993–0002, 301–796–6652, e-mail: [Katherine.serrano@fda.hhs.gov](mailto:Katherine.serrano@fda.hhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background

In the *Federal Register* of June 17, 2010 (75 FR 34463), FDA published a notice announcing a public meeting that is intended to create a forum for interested stakeholders to discuss the agency’s oversight of laboratory developed tests. FDA announced in the notice that it is seeking input and requesting comments on this topic. The June 17, 2010, notice invited individuals interested in presenting to register by July 12, 2010. Registration to present at the public meeting is closed. All others are welcome to attend on a first-come, first-served basis.

Because of greater than anticipated response for attending the public meeting, FDA is announcing in this notice a new location for the public meeting.

##### II. New Location for the Public Workshop

The new location will be The Marriott Inn & Conference Center, University of Maryland University College (see **ADDRESSES**). Directions and information on parking, accommodations, and transportation options can be found at: <http://www.marriott.com/hotels/travel/wasum-the-marriott-inn-and-conference-center-university-of-maryland-university-college/>.

Dated: July 7, 2010.

**Nancy Stade,**

*Acting Associate Director for Regulations and Policy, Center for Devices and Radiological Health.*

[FR Doc. 2010–16974 Filed 7–12–10; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Notice of a Conference Call of the NIH Scientific Management Review Board

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a conference call meeting of the Scientific Management Review Board.

The NIH Reform Act of 2006 (Pub. L. 109–482) provides organizational authorities to HHS and NIH officials to: (1) Establish or abolish national research institutes; (2) reorganize the offices within the Office of the Director, NIH including adding, removing, or transferring the functions of such offices or establishing or terminating such offices; and (3) reorganize, divisions, centers, or other administrative units within an NIH national research institute or national center including adding, removing, or transferring the functions of such units, or establishing or terminating such units. The purpose of the Scientific Management Review Board (also referred to as SMRB or Board) is to advise appropriate HHS and NIH officials on the use of these organizational authorities and identify the reasons underlying the recommendations.

**Name of Committee:** Scientific Management Review Board.

**Date:** July 26, 2010.

**Time:** 10:30 a.m. to 12 p.m. (EST)

**Agenda:** Presentation will include an overview and discussion of a new charge to the SMRB, which entails considering the attributes and functions of a translational medicine program optimized to accelerate therapeutics development. Time will be allotted on the agenda for public comment. To sign up for public comment, please submit your name and affiliation to the contact person listed below by July 25, 2010. Sign up will be restricted to one sign up per email. In the event that time does not allow for all those interested to present oral comments, anyone may file written comments using the contact person address below.

**Dial-In Information:** The toll-free number to participate in this call is 1–800–779–1545. Indicate to the conference operator that your participant pass code is “NIH”.

**Contact Person:** Dr. Lyric Jorgenson, Office of Science Policy, Office of the Director, NIH, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, (301) 496–6837, [smrb@mail.nih.gov](mailto:smrb@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

The draft agenda, meeting materials, dial-in information, and other information about the SMRB, will be available at <http://smrb.od.nih.gov>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate